Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 155

1.

[Prostate cancer microenvironment: Its structure, functions and therapeutic applications].

Lorion R, Bladou F, Spatz A, van Kempen L, Irani J.

Prog Urol. 2016 Jul 13. pii: S1166-7087(16)30074-4. doi: 10.1016/j.purol.2016.06.006. [Epub ahead of print] French.

PMID:
27423973
2.

PAX6 est un modulateur de l'activité transcriptionnelle du récepteur aux androgènes dans le cancer de prostate.

Lagabrielle S, Janssen S, Elchebly M, Bladou F, Spatz A, Van Kempen L.

Prog Urol. 2015 Nov;25(13):735. doi: 10.1016/j.purol.2015.08.039. French. No abstract available.

PMID:
26544233
3.

Biopsy characteristics in men with a preoperative diagnosis of prostatic adenocarcinoma with high Gleason score (8-10) predict pathologic outcome in radical prostatectomy.

Brimo F, Xu B, Scarlata E, Bégin LR, Spatz A, Salomon L, Zakaria AS, Ploussard G, Bladou F, Kassouf W, Tanguay S, Chevalier S, Ye H, Aprikian A.

Hum Pathol. 2014 Oct;45(10):2006-13. doi: 10.1016/j.humpath.2014.06.014. Epub 2014 Jul 2.

PMID:
25152453
4.

From biomarker development towards implementation of multidimensional biomarker panels in a clinical setting.

van Kempen LC, Spatz A.

Mol Oncol. 2014 Jun;8(4):781-2. doi: 10.1016/j.molonc.2014.05.002. Epub 2014 May 14. No abstract available.

5.

The validity of circulating microRNAs in oncology: five years of challenges and contradictions.

Jarry J, Schadendorf D, Greenwood C, Spatz A, van Kempen LC.

Mol Oncol. 2014 Jun;8(4):819-29. doi: 10.1016/j.molonc.2014.02.009. Epub 2014 Mar 6. Review.

6.

Neonicotinoids interfere with specific components of navigation in honeybees.

Fischer J, Müller T, Spatz AK, Greggers U, Grünewald B, Menzel R.

PLoS One. 2014 Mar 19;9(3):e91364. doi: 10.1371/journal.pone.0091364. eCollection 2014.

7.

Cutaneous melanoma.

Eggermont AM, Spatz A, Robert C.

Lancet. 2014 Mar 1;383(9919):816-27. doi: 10.1016/S0140-6736(13)60802-8. Epub 2013 Sep 19. Review.

PMID:
24054424
8.

Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial.

Eggermont AM, Suciu S, Rutkowski P, Marsden J, Santinami M, Corrie P, Aamdal S, Ascierto PA, Patel PM, Kruit WH, Bastholt L, Borgognoni L, Bernengo MG, Davidson N, Polders L, Praet M, Spatz A.

J Clin Oncol. 2013 Oct 20;31(30):3831-7. doi: 10.1200/JCO.2012.47.9303. Epub 2013 Sep 9.

9.

Biopsies: next-generation biospecimens for tailoring therapy.

Basik M, Aguilar-Mahecha A, Rousseau C, Diaz Z, Tejpar S, Spatz A, Greenwood CM, Batist G.

Nat Rev Clin Oncol. 2013 Aug;10(8):437-50. doi: 10.1038/nrclinonc.2013.101. Epub 2013 Jun 25. Review. Erratum in: Nat Rev Clin Oncol. 2013 Nov;10(11):608.

PMID:
23799370
10.

Next-generation biobanking of metastases to enable multidimensional molecular profiling in personalized medicine.

Diaz Z, Aguilar-Mahecha A, Paquet ER, Basik M, Orain M, Camlioglu E, Constantin A, Benlimame N, Bachvarov D, Jannot G, Simard MJ, Chabot B, Gologan A, Klinck R, Gagnon-Kugler T, Lespérance B, Samson B, Kavan P, Alcindor T, Dalfen R, Lan C, Chabot C, Buchanan M, Przybytkowski E, Qureshi S, Rousseau C, Spatz A, Têtu B, Batist G.

Mod Pathol. 2013 Nov;26(11):1413-24. doi: 10.1038/modpathol.2013.81. Epub 2013 Jun 7.

11.

Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma.

Kruit WH, Suciu S, Dreno B, Mortier L, Robert C, Chiarion-Sileni V, Maio M, Testori A, Dorval T, Grob JJ, Becker JC, Spatz A, Eggermont AM, Louahed J, Lehmann FF, Brichard VG, Keilholz U.

J Clin Oncol. 2013 Jul 1;31(19):2413-20. doi: 10.1200/JCO.2012.43.7111. Epub 2013 May 28.

12.

Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study).

Busse A, Rapion J, Fusi A, Suciu S, Nonnenmacher A, Santinami M, Kruit WH, Testori A, Punt CJ, Dalgleish AG, Spatz A, Eggermont AM, Keilholz U.

Cancer Immunol Immunother. 2013 Jul;62(7):1223-33. doi: 10.1007/s00262-013-1428-4. Epub 2013 Apr 27.

PMID:
23624802
13.

Tyrosinase-related protein 1 mRNA expression in lymph node metastases predicts overall survival in high-risk melanoma patients.

El Hajj P, Journe F, Wiedig M, Laios I, Salès F, Galibert MD, Van Kempen LC, Spatz A, Badran B, Larsimont D, Awada A, Ghanem G.

Br J Cancer. 2013 Apr 30;108(8):1641-7. doi: 10.1038/bjc.2013.115. Epub 2013 Mar 21.

14.

Barriers and facilitators of adherence to medical advice on skin self-examination during melanoma follow-up care.

Körner A, Drapeau M, Thombs BD, Rosberger Z, Wang B, Khanna M, Spatz A, Coroiu A, Garland R, Batist G.

BMC Dermatol. 2013 Mar 1;13:3. doi: 10.1186/1471-5945-13-3.

15.

Immediate effects of a brief mindfulness-based body scan on patients with chronic pain.

Ussher M, Spatz A, Copland C, Nicolaou A, Cargill A, Amini-Tabrizi N, McCracken LM.

J Behav Med. 2014 Feb;37(1):127-34. doi: 10.1007/s10865-012-9466-5. Epub 2012 Nov 6.

PMID:
23129105
16.

EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors?

Paliga A, Onerheim R, Gologan A, Chong G, Spatz A, Niazi T, Garant A, Macheto D, Alcindor T, Vuong T.

Br J Cancer. 2012 Nov 20;107(11):1864-8. doi: 10.1038/bjc.2012.479. Epub 2012 Oct 23.

17.

Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.

Eggermont AM, Suciu S, Testori A, Santinami M, Kruit WH, Marsden J, Punt CJ, Salès F, Dummer R, Robert C, Schadendorf D, Patel PM, de Schaetzen G, Spatz A, Keilholz U.

J Clin Oncol. 2012 Nov 1;30(31):3810-8. doi: 10.1200/JCO.2011.41.3799. Epub 2012 Sep 24.

18.

Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline--Update 2012.

Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Spatz A, Grob JJ, Malvehy J, Newton-Bishop J, Stratigos A, Pehamberger H, Eggermont AM; European Dermatology Forum; European Association of Dermato-Oncology; European Organization of Research and Treatment of Cancer.

Eur J Cancer. 2012 Oct;48(15):2375-90. doi: 10.1016/j.ejca.2012.06.013. Epub 2012 Sep 13.

PMID:
22981501
19.

Loss of microRNA-200a and c, and microRNA-203 expression at the invasive front of primary cutaneous melanoma is associated with increased thickness and disease progression.

van Kempen LC, van den Hurk K, Lazar V, Michiels S, Winnepenninckx V, Stas M, Spatz A, van den Oord JJ.

Virchows Arch. 2012 Oct;461(4):441-8. doi: 10.1007/s00428-012-1309-9. Epub 2012 Sep 6.

PMID:
22956368
20.

The role of molecular pathology in non-small-cell lung carcinoma-now and in the future.

Brandao GD, Brega EF, Spatz A.

Curr Oncol. 2012 Jun;19(Suppl 1):S24-32. doi: 10.3747/co.19.1058.

Items per page

Supplemental Content

Write to the Help Desk